Abstract
Phenytoin is effective in suppressing tonic-clonic and partial seizures, and is widely used for initial therapy, particularly in adults. Ninety percent of phenytoin is protein bound and entirely eliminated by hepatic metabolism. The major metabolite of phenytoin, 5-(p-hydroxyphenyl)-5phenylhy-dantoin (5HPPH) is excreted in the urine. Higher phenytoin levels for a given dose of phenytoin can be seen in alcohol intoxication, hepatic and renal failures, hypoalbuminemia, nephrotic syndrome, trauma, and AIDS. Noncompliance can lead to accumulation of the drug-causing toxicity. We present a patient with acute alcohol intoxication who developed phenytoin toxicity due to noncompliance with the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
- Brandolese R., Scordo M. G., Spina E., Gusella M., Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther. 2001 Oct;70(4):391–394. [PubMed] [Google Scholar]
- KUTT H., WOLK M., SCHERMAN R., MCDOWELL F. INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY. Neurology. 1964 Jun;14:542–548. doi: 10.1212/wnl.14.6.542. [DOI] [PubMed] [Google Scholar]
- Kidd R. S., Curry T. B., Gallagher S., Edeki T., Blaisdell J., Goldstein J. A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803–808. doi: 10.1097/00008571-200112000-00008. [DOI] [PubMed] [Google Scholar]
- Kutt H., Haynes J., McDowell F. Some causes of ineffectiveness of diphenylhydantoin. Arch Neurol. 1966 May;14(5):489–492. doi: 10.1001/archneur.1966.00470110033004. [DOI] [PubMed] [Google Scholar]
- Pitner J. K., Long L. D., Meyer R. P., Pennypacker L. C. Phenytoin toxicity in an older patient with slow metabolism and atypical presentation. Pharmacotherapy. 1998 Jan-Feb;18(1):218–225. [PubMed] [Google Scholar]
- Vasko M. R., Bell R. D., Daly D. D., Pippenger C. E. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther. 1980 Jan;27(1):96–103. doi: 10.1038/clpt.1980.15. [DOI] [PubMed] [Google Scholar]
- Watanabe M., Iwahashi K., Kugoh T., Suwaki H. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. Clin Neuropharmacol. 1997 Aug;20(4):346–351. doi: 10.1097/00002826-199708000-00006. [DOI] [PubMed] [Google Scholar]